25 Years of HIV/AIDS Science: Reaching the Poor with Research Advances  by Fauci, Anthony S.
Leading Edge
CommentaryBy the end of 2006—25 years after 
the first reported AIDS cases in the 
United States—the HIV/AIDS pan-
demic had claimed more than 25 
million lives globally (UNAIDS/WHO, 
2006). What began as a handful of 
recognized cases among homosexual 
men in the early 1980s has become a 
global pandemic of such proportions 
that it clearly ranks as one of the most 
destructive microbial scourges in his-
tory (UNAIDS, 2006; Fauci, 2006).
Of the ~40 million people living with 
HIV, the vast majority live in resource-
poor settings, notably countries of 
sub-Saharan Africa where food inse-
curity and endemic infections such as 
tuberculosis, malaria, and a range of 
parasitic diseases are also common 
(UNAIDS, 2006). Of the 62 countries 
most affected by HIV (nations with 
adult HIV seroprevalence rates >1% 
or with large numbers of persons liv-
ing with HIV), 40 are in sub-Saharan 
Africa, 5 in Asia, 12 in the Americas 
and the Caribbean, 4 in Europe, and 
1 in Oceania (United Nations Popula-
tion Division, 2006). According to the 
United Nations Population Division, 
life expectancy in southern Africa as 
a whole has fallen from 61 to 49 years 
over the last 20 years. In the countries 
hardest hit by HIV/AIDS, the situation 
is even more severe: in Zimbabwe, for 
example, estimated life expectancy at 
birth is only 34 years for women and 
37 years for men.
In addition to the enormous human 
tragedy associated with HIV/AIDS, the 
economic costs are staggering, pos-
ing serious impediments to the growth 
and stability of many developing 
countries (Bertozzi et al., 2006). HIV/
AIDS has disproportionately affected 
young and middle-aged adults who 
are the mainstays of economies and 
the breadwinners for families. In many 
developing countries, previously real-
ized gains in economic and social 
development have been reversed as 
HIV/AIDS has reduced the labor sup-
ply and productivity and depleted lim-
ited pools of skilled workers, teachers, 
and managers. In communities with 
large numbers of HIV-infected individ-
uals, poverty and other development 
challenges have worsened. An exac-
erbation of poverty in turn reduces job 
opportunities and makes populations 
more vulnerable to the spread of HIV.
As the humanitarian and economic 
burden of HIV/AIDS has grown, so too 
has the biomedical research response 
to the pandemic, providing important 
opportunities to mitigate the impact 
of HIV/AIDS on health and economic 
development. Funding for HIV/AIDS-
related research is unprecedented in 
magnitude, larger than for any other 
single disease in history (Folkers and 
Fauci, 2001). At the US National Insti-
tutes of Health alone, >$30 billion has 
been spent on HIV/AIDS research 
since the beginning of the pandemic 
(Fauci, 2006). The returns on these 
investments have been substantial 
(reviewed in Fauci, 2003). Within 3 
years of the recognition of the first 
AIDS cases in 1981, the etiologic agent 
of the syndrome was discovered and 
causality proven. In 1985, a sensitive 
and specific diagnostic assay for HIV 
antibodies was developed. This test 
and its descendents have been used 
in epidemiological studies to illuminate 
the scope of the epidemic, as well as 
to safeguard blood supplies. Molecu-
lar studies of HIV have delineated the 
genetic and structural organization of 
the virus and the mechanisms that 
regulate its replication. This infor-
mation and related research on HIV 
pathogenesis has facilitated the rapid 
development of antiretroviral drugs 
(ARVs) that limit HIV replication and 
immune system damage, as well as 
tools to monitor levels of virus in the 
blood and immune status. More than 
25 antiretroviral drugs are now avail-
able to treat HIV infection, and these 
medications have had an enormous 
impact in reducing morbidity and 
mortality wherever they have been 
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used (WHO/UNAIDS/UNICEF, 2007). 
New ARVs such as integrase, matu-
ration, and entry inhibitors, as well as 
next-generation reverse transcriptase 
inhibitors and protease inhibitors, have 
been licensed or are in late-stage clini-
cal development. These drugs hold 
great promise, especially for patients 
who have failed their current regimens 
due to drug resistance or other factors 
(Siegel and Gulick, 2007).
Encouragingly, growing numbers 
of HIV-infected individuals in need 
of ARVs in low- and middle-income 
countries are receiving them. A grow-
ing body of evidence has shown that 
the immunological and virological 
responses to ARVs in both adults 
and children in poor countries can 
be as good as those in industrialized 
settings. ARV prices have fallen dra-
matically: the average annual cost in 
low- and middle-income countries 
of a common first-line ARV regimen 
consisting of 3 medications was 
<$150 in 2006. Programs such as 
the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR), the Global 
Fund to Fight AIDS, Tuberculosis, 
and Malaria, nongovernmental orga-
nizations such as Medecins Sans 
Frontieres, and philanthropies like the 
Bill and Melinda Gates Foundation 
and the Clinton Foundation helped 
deliver ARVs to >2 million individuals 
by the end of 2006, up from 400,000 
in December, 2003 (see Figure 1) 
(WHO/UNAIDS/UNICEF, 2007). This 
progress demonstrates what can be 
accomplished even in the develop-
ing world with increased funding, a 
strong global commitment, collective 
action, and political will.
Significant progress also has been 
made in HIV prevention. The risk fac-
tors associated with HIV transmis-
sion are well defined, and proven 
methods to prevent sexual HIV trans-
mission (e.g., behavior change pro-
grams, condom promotion), blood-
borne HIV transmission (e.g., needle/
syringe exchanges), and mother-to-
child transmission (e.g., ARVs) have 
been deployed throughout the world 
(Global HIV Prevention Working 
Group, 2007). No single intervention 
is a magic bullet but when deployed 
in combination can have an important 
impact, as evidenced by well-docu-
mented success in Brazil, Thailand, 
Uganda, Senegal, and other coun-
tries, both rich and poor.
Promising research on new pre-
vention interventions holds hope for 
adding new tools to the HIV preven-
tion armamentarium, such as adult 
male circumcision, topical microbi-
cides, pre-exposure chemoprophy-
laxis with well-tolerated ARVs such 
as tenofovir, and an HIV vaccine 
(Bertozzi et al., 2006). A preven-
tive HIV vaccine remains the great-
est hope for reversing the relentless 
spread of HIV, and clinical trials of 
diverse approaches are ongoing 
throughout the world (Johnston and 
Fauci, 2007). Even an “imperfect” 
HIV vaccine would have enormous 
benefits. In this regard, progress has 
been made in developing so-called 
Figure 1. ARV Therapy for AIDS Patients
Estimated number of HIV-infected people receiving antiretroviral therapy in low- and middle-
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evoke cell-mediated immunity that 
may not protect against infection 
but could nonetheless help lower 
the initial burst of viremia following 
infection as well as the viral set point 
and slow disease progression and 
reduce transmissibility. Meanwhile, 
structural studies of the HIV enve-
lope may lead to the development 
of immunogens that elicit broadly 
neutralizing antibodies that could 
form the basis of a “sterilizing” vac-
cine that blocks infection altogether 
(Johnston and Fauci, 2007).
While extraordinary scientific, 
medical, and public health accom-
plishments have been made in 
the battle against HIV/AIDS, much 
remains to be done, especially with 
regard to delivering the fruits of the 
research endeavor to resource-poor 
countries where the pandemic con-
tinues to destroy lives, communities, 
and societies in staggering num-
bers (Global HIV Prevention Work-
ing Group, 2007). Evidence-based 
HIV interventions are needed at high 
levels of coverage, uptake, intensity, 
and duration if they are to have a sig-
nificant public health impact. Priori-
ties include the effective scale-up of 
HIV/AIDS therapy, care, and preven-
tion, training of health care workers 
and ancillary personnel, support of 
orphans and vulnerable children, and 
the strengthening of health care sys-
tems and infrastructure in HIV-bur-
dened regions (UNAIDS, 2006). Each 
of these will require an increased and 
sustained infusion of resources from 
rich countries and other donors. It is 
encouraging that annual spending on 
HIV/AIDS in poor- and middle-income 
countries increased six-fold between 
2001 and 2007 to approximately $10 
billion, but this sum represents less 
than half the amount that UNAIDS 
estimates will be needed in 2008 for 
the expanded response needed to 
slow the pandemic.
Despite the progress with ARV 
access noted above, huge gaps 
remain in the provision of these life-
saving drugs. Only 28% of people (and 
just 15% of children) in need of ARVs 
in low- and middle-income countries 
are receiving them, and problems of 
access persist in developed countries 
as well (see Figure 1). A shortage of 
trained health care workers remains 
an important rate-limiting factor in 
the scale-up of HIV treatment and 
prevention services, especially in 
Africa. The World Health Organiza-
tion (WHO) has estimated that Africa 
bears ~24% of the global burden of 
all diseases but has only 3% of the 
world’s healthcare workforce. Of 
57 countries that do not meet basic 
standards of healthcare coverage by 
doctors, nurses, and midwives, 36 are 
in Sub-Saharan Africa (Kumar, 2007). 
Significant resources are needed to 
train doctors and nurses in resource-
poor areas, as well as community 
healthcare workers to provide care for 
HIV/AIDS and other diseases in their 
home villages and neighborhoods. 
The model of community-based 
care provided by closely supervised 
“accompagnateurs,” trained com-
munity health workers who use sim-
plified algorithms for diagnosis and 
treatment, has been validated in both 
rich and poor countries and must be 
better utilized (Kim and Farmer, 2006; 
Mukherjee et al., 2003). Operational 
and clinical research is essential to 
guide the formulation of such algo-
rithms and to assess their utility on a 
larger scale.
Infrastructure and personnel 
for the medical monitoring of ARV 
therapy are lacking in most poor 
communities (Koenig et al., 2006). 
Clearly, limited resources should 
first be used to scale-up ARV treat-
ment and provide basic support to 
patients to achieve good treatment 
adherence and minimize resistance. 
As rapidly as possible, however, lab-
oratory capacity must be improved 
to allow the monitoring of virologi-
cal and immunological outcomes of 
ARV therapy, as well as toxicities, 
such that treatment regimens can 
be optimized (Koenig et al., 2006). 
Increased funding also is needed 
to provide services that allow poor 
people to overcome the social and 
economic impediments to success-
ful adherence to HIV/AIDS treatment 
and care. So-called “wrap-around 
services” frequently include food 
supplements, transportation to clin-ics, child care, and housing, as well 
as care for concomitant diseases 
(Kim and Farmer, 2006; Mukherjee 
et al., 2003).
Striving for universal access to 
ARVs is a public health and ethical 
imperative; however, it may be logisti-
cally impossible to reach this goal, as 
six people were newly infected with 
HIV in 2006 for every person put on 
treatment (WHO/UNAIDS/UNICEF, 
2007). Therefore, HIV prevention 
activities, hopefully with, but possi-
bly without, a safe and effective HIV/
AIDS vaccine will determine the tra-
jectory and burden of the HIV/AIDS 
pandemic in the years and decades 
ahead. Today, fewer than one person 
in five at risk of becoming infected 
with HIV has access to HIV preven-
tion services, which even when avail-
able are confounded by complex cul-
tural and societal issues (Global HIV 
Prevention Working Group, 2007). For 
example, a condom is used in only 
9% of sex acts involving nonregular 
partners. Just 10%–12% of adults in 
the most heavily affected countries in 
sub-Saharan Africa have been tested 
and know their HIV serostatus. In 
developed countries, near-universal 
provision of ARVs to prevent mother-
to-child transmission (PMTCT) has 
reduced perinatal infection rates to 
<1%–2% in many cohorts; however, 
in developing countries, just 11% of 
HIV-infected pregnant women receive 
ARV prophylaxis for PMTCT. Preven-
tion services reach a very low propor-
tion of individuals in poor countries at 
highest risk of HIV infection: just 9% 
of men who have sex with men, 8% 
of injection drug users, and <20% of 
commercial sex workers (Global HIV 
Prevention Working Group, 2007).
The delivery of proven prevention 
services is imperative: half of the 60 
million HIV infections projected to 
occur globally between 2005 and 
2015 could be averted with compre-
hensive scale-up of proven prevention 
strategies, according to a recent esti-
mate (Global HIV Prevention Working 
Group, 2007). In scaling up preven-
tion services, important lessons can 
be drawn from common elements 
of the HIV/AIDS prevention efforts in 
those countries that have had suc-Cell 131, Nocess in reducing HIV infections. Such 
factors include the strong support of 
political leaders and the use of the 
media to raise HIV awareness; efforts 
to encourage respect, tolerance, and 
compassion for HIV-infected people; 
adequate and sustained funding; the 
use of evidence-based strategies 
based on a detailed understanding of 
the specific dynamics and epidemi-
ology of the epidemic in a particular 
setting; and the involvement in the 
prevention effort of diverse sectors, 
including community groups and reli-
gious leaders (Global HIV Prevention 
Working Group, 2007).
Concomitantly, further research is 
needed on how best to deliver adult 
male circumcision (a prevention 
tool with significant efficacy in clini-
cal trials) and integrate it into exist-
ing health services. Research also 
is needed to prove the efficacy and 
feasibility of other promising HIV pre-
vention approaches such as topical 
microbicides, pre-exposure chemo-
prophylaxis, and an HIV vaccine 
(Johnston and Fauci, 2007). Each of 
these interventions could have a sig-
nificant impact on the course of the 
HIV pandemic, as part of a multifac-
torial prevention effort.
A truly comprehensive approach 
to HIV disease will require a com-
mitment to overcoming the stigma 
and discrimination frequently asso-
ciated with HIV infection (UNAIDS, 
2006). The medical consequences 
of stigma and discrimination are 
serious because HIV-infected peo-
ple may avoid lifesaving treatment 
and suffer needlessly. In addition, 
the psychological toll of isolation 
and ostracism can be profound, 
to say nothing of the physical vio-
lence to which HIV-infected people 
are sometimes exposed. Because 
of stigma, at-risk people may avoid 
HIV testing altogether, missing 
opportunities for needed treatment 
and opportunities to access preven-
tion programs that could help them 
avoid infecting others.
As we enter the second quarter 
century of AIDS, we are at a pivotal 
juncture: there have been substan-
tial scientific advances, yet many 
infected people are dying needlessly vember 2, 2007 ©2007 Elsevier Inc. 431
and HIV infection is still spread-
ing. Collectively, we must do more 
to slow the spread of HIV/AIDS by 
scaling up the availability of proven 
treatments and prevention tools. 
We must eliminate stigma toward 
and discrimination against people 
with HIV and refine and validate the 
efficacy of existing treatment and 
prevention programs. We must fur-
ther elucidate the pathogenesis of 
this complex disease and develop 
improved treatments and tools for 
prevention. Perhaps most impor-
tant, public health workers, policy-
makers, and activists must bring 
the benefits of advances in treat-
ment and prevention research to the 
people who need them most.
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